Evidence profile
Retatrutide (50 mg Vial)
Retatrutide is being developed as an agonist of three metabolic hormone receptors. Published phase 2 and phase 3 findings provide clinical evidence, while approval and the identity of a retail product remain separate questions.
01
Product identity
Trial material is not interchangeable with a retail research vial on the basis of the name alone.
The supplier heading reads “Retatrutide | 50mg”, but a size field in its description says 10mg. The linked heading identifies this catalogue variant; the amount and formulation of supplied stock require confirmation before any quantity is used.[9]
02
What has been studied
Primary human study
Published phase 2 obesity evidence
- Population or model
- 338 adults with obesity, or overweight with a related condition
- Study route or material
- Subcutaneous in a controlled trial
In a 338-participant randomized obesity trial, retatrutide produced greater weight reduction than placebo. Gastrointestinal adverse events and changes in heart rate were also reported.[1]
Primary human study
A phase 2 diabetes trial included an active comparator
- Population or model
- 281 randomized adults with type 2 diabetes; 275 included in efficacy analyses
- Study route or material
- Subcutaneous in a controlled trial
A separate trial randomized 281 adults with type 2 diabetes to retatrutide, dulaglutide or placebo; 275 entered the efficacy analyses. It assessed HbA1c at 24 weeks and additional glycaemic and weight outcomes at 36 weeks. Comparisons varied by treatment arm, and gastrointestinal adverse events were reported. This was not a comparison with tirzepatide or semaglutide.[2]
Primary human study
Published phase 3 diabetes evidence
- Population or model
- 537 adults with type 2 diabetes inadequately controlled by diet and exercise alone
- Study route or material
- Subcutaneous in a controlled trial
TRANSCEND-T2D-1, published in June 2026, randomized 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone. At 40 weeks, the study reported greater HbA1c and bodyweight reductions than placebo. Gastrointestinal events and treatment discontinuations due to adverse events were also reported.[3]
Trial registry
A direct comparison is registered; results are not posted
- Population or model
- Adults with obesity; phase 3 active-comparator study
- Study route or material
- Subcutaneous in the registered trial
TRIUMPH-5 compares retatrutide with tirzepatide in adults with obesity. The registry listed active, not recruiting status and no posted results on 9 September 2026. It cannot yet supply a result comparing the two treatments.[4]
Developer update
An active development program
- Population or model
- Clinical-trial populations
- Study route or material
- Investigational trials
The developer also reports continuing phase 3 progress. Sponsor announcements and published trial papers are identified as different source types.[6]
03
Evidence limits
The reviewed evidence does not establish the identity, purity, sterility or stability of an online research product.
A trial schedule is not a patient instruction for a supplier vial.
The reviewed sources do not establish patient instructions for this product. No dose, cycle, preparation method or administration schedule is provided here.
04
Formulation and handling evidence
Actual content of each vial size and linkage to the current stock sample.
No research-vial preparation or dosing information should be inferred from a branded clinical-development program.
A compatible diluent, prepared-solution stability and container/device compatibility must be supported for the exact formulation. The diluent manufacturer’s instructions do not supply a universal storage period for every dissolved substance.[8]
05
Approval context
Lilly Canada’s August 2026 notice identifies retatrutide as investigational and unapproved. That notice was checked on 9 September 2026. The linked supplier research vial is not an authorized retatrutide medicine.[5][7]
06
Sources and review scope
- Retatrutide phase 2 obesity trialPrimary human study · Abstract and indexed identity · Checked 2026-09-08
- Retatrutide phase 2 diabetes trial with dulaglutide and placebo comparatorsPrimary human study · Primary indexed abstract via Europe PMC; full paper and supplement not assessed · Checked 2026-09-08
- TRANSCEND-T2D-1: published phase 3 retatrutide diabetes trialPrimary human study · Primary indexed abstract via Europe PMC; full paper and supplement not assessed · Checked 2026-09-08
- TRIUMPH-5: retatrutide versus tirzepatide trial registrationTrial registry · Fresh official ClinicalTrials.gov API status, intervention and results-posting record · Checked 2026-09-09
- Lilly Canada retatrutide public noticeDeveloper status statement · Fresh Lilly Canada notice, investigational and unapproved status passage · Checked 2026-09-09
- Retatrutide development-program updateDeveloper update · Current developer page · Checked 2026-09-08
- Health Canada: unauthorized injectable peptide productsRegulatory advisory · Fresh Health Canada advisory read, including product/DIN and RUO-label limits · Checked 2026-09-09
- Hospira/Pfizer: bacteriostatic water manufacturer informationManufacturer information; US presentation · Fresh manufacturer page, relevant compatibility/storage/supply passages · Checked 2026-09-09
- Amino Labs: Retatrutide | 50mgSupplier listing; identity reference · Exact heading, SKU, form and supplier URL from the full catalogue capture; not stock-lot authentication · Checked 2026-09-09
This is a selected-source evidence summary. It is not a systematic review, formal certainty grade or qualified clinical sign-off. Study dates and source-check dates are distinct.